Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacological profiling of a berbamine derivative for lymphoma treatment

ABSTRACT: Pharmacological profiling of a berbamine derivative for lymphoma treatment

PROVIDER: PRJNA1028599 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26397789_1.fastq.gz	Fastqsanger.gz
	SRR26397789_2.fastq.gz	Fastqsanger.gz
	SRR26397790_1.fastq.gz	Fastqsanger.gz
	SRR26397790_2.fastq.gz	Fastqsanger.gz
	SRR26397791_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Pharmacological profiling of a berbamine derivative for lymphoma treatment

Project description:Ca2+/calmodulin-dependent protein kinase II gamma (CAMKIIγ) has been identified as a potential target for treating cancer. Based on our previous study of Berbamine (BBM) as a CAMKIIγ inhibitor, we have synthesized a new BBM derivative termed PA4. Compared to BBM, PA4 showed improved potency and specificity, and was more cytotoxic against lymphoma and leukemia compared to other types of cancer. In addition to indirectly targeting c-Myc protein stability, we demonstrated that its cytotoxic effects were also mediated via increased ROS production in lymphoma cells. PA4 significantly impeded tumor growth in vivo in a xenograft T-cell lymphoma (TCL) mouse model. Pharmacokinetics studies depicted quick absorption into plasma after oral administration with a max concentration of 1680 ± 479 ng/mL at 5.33 ± 2.31 hr. The calculated oral absolute bioavailability was 34.1%. Toxicity assessment of PA4 showed that the therapeutic window used in our experiments was safe for future development. Given its efficacy, safety, and favorable pharmacokinetic profile, PA4 is a potential lead candidate for treating lymphoma.

2024-02-14 | GSE245491 | GEO

Pharmacological profiling of a berbamine derivative for lymphoma treatment.

Project description: Not available

| S-EPMC10824694 | biostudies-literature

Thermal Proteome Profiling Chlorotonil derivative in S. aureus USA300

Project description:The protein targets of Chlorotonil derivative ChB1-Epo2 were analysed by thermal proteome profiling in S. aureus USA300 cells.

2025-03-08 | PXD051670 | Pride

Pharmacological and genomic profiling identifies NFκB-targeted treatment strategies for mantle cell lymphoma

Project description:Mantle cell lymphoma (MCL) is an aggressive malignancy characterized by poor prognosis, underscoring the need for novel therapeutic strategies1. In this study, we employed large-scale pharmacological profiling of 16 pathway inhibitors across more than 100 hematological cell line models to identify novel therapeutic approaches. This screen identified a subset of MCL cell lines that were highly sensitive to the B-cell receptor (BCR) signaling inhibitors ibrutinib and sotrastaurin (STN), which are currently in clinical trials2, 3. Sensitive MCL models exhibited chronic activation of the CARD11-BCL10-MALT1 (CBM) complex and dependency on downstream classical NFκB signaling. In contrast, insensitive cell lines displayed activation of the alternative NFκB pathway. Massively parallel transcriptome sequencing identified mutations in negative regulators of the alternative NFκB pathway in ibrutinib-insensitive cell lines. Notably, sequencing of 165 MCL patient samples revealed that components of the alternative NFκB pathway, particularly TRAF2 and BIRC3, are mutated in roughly 15% of MCL patients. Functional analyses of patient-derived BIRC3 mutant alleles indicated that these are loss-of-function mutants that constitutively activate alternative NFκB signaling. While being associated with insensitivity to ibrutinib, genetic lesions in the alternative pathway conferred dependence on NIK, a kinase that mediates signaling downstream of the TRAF2/3-BIRC2/3 complex. Thus, NIK represents a novel therapeutic target for MCL treatment, particularly for tumors refractory to BCR pathway inhibitors. Collectively, these findings reveal a pattern of mutually exclusive activation of the CBM-NFκB or alternative NIK-NFκB pathways in MCL and provide critical insights into patient stratification strategies for NFκB-pathway targeted agents.

| EGAS00001000622 | EGA

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models

Project description:CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortide, as single agents and in combination, in various B-cell lymphoma models.

2026-07-01 | GSE303336 | GEO

murine MYC-dependent lymphoma cells: Dox vs. NoDox treatment

Project description:miRNA expression profiling of murine MYC-dependent lymphoma cell lines harboring the MYC-transgene in a Tet-off system comparing control untreated lymphoma cells (high MYC expression state) with 18hours Dox treated lymphoma cells (low MYC expression state). Keywords: inducible expression system Two-condition experiment, Dox vs. NoDox treatment. Biological replicates: 26 distinct cell lines, 1 technical replicate. Four replicates per array.

2010-05-25 | E-GEOD-12394 | biostudies-arrayexpress

Transcriptome profiling of B-cell lymphoma cells with pharmacological inhibition of KDM5A/B by using the inhibitor JQKD82

Project description:Transcriptome profiling of B-cell lymphoma cells with pharmacological inhibition of KDM5A/B by using the inhibitor JQKD82

| PRJNA1367136 | ENA

Gene Expression Profiling of T- and NK-cell Lymphoma Cell Cultures

Project description:RNA-seq gene expression profiling was performed on 30 established T- and NK-cell lymphoma cell cultures. These data were collected to for the measurement of correlations between gene expression profiling and the sensitivities of T- and NK-cell lymphoma cultures to small molecule therapies used in the treatment of T- and NK- lymphomas.

2026-04-01 | GSE325206 | GEO

murine MYC-dependent lymphoma cells: Dox vs. NoDox treatment

2008-08-12 | GSE12394 | GEO

Transcriptomic profiling of MCL-1 inhibitor response in lymphoma models in vitro and in vivo

Project description:This study presents single-cell RNA sequencing (scRNA-seq) profiling of lymphoma models treated with the MCL-1 inhibitor S63845. Human Namalwa lymphoma cellsand mouse Eμ-Myc lymphoma spleen samples were analyzed following vehicle control or S63845 treatment at defined time points to characterize transcriptional responses associated with drug sensitivity, persistence, and resistance.

2026-03-11 | GSE314230 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data